Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acutus Medical, Inc.AFIB · Entity 83848 | Director · Chief Executive Officer | April 01, 2022 | April 05, 2022 |
| TELA Bio, Inc.TELA · Entity 7381 | Director | May 28, 2025 | May 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acutus Medical, Inc.
Report date April 01, 2022 · Filed April 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,469 |
Reported balance
After 2022-04-01 transaction · row 1
1 source rowRow 1 · 2022-04-01 · Tax withholding · Disposed 3,896 · Balance 61,469 F1: Represents shares that have been withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of (and related delivery of shares underlying) restricted stock units reported on a Form 4 filed on April 2, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that have been withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of (and related delivery of shares underlying) restricted stock units reported on a Form 4 filed on April 2, 2021.
TELA Bio, Inc.
Report date May 28, 2025 · Filed May 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,330 |
Reported balance
After 2025-05-28 transaction · row 1
1 source rowRow 1 · 2025-05-28 · Grant · Acquired 7,950 · Balance 23,330 F1: These restricted stock units vest on the earlier of (a) May 28, 2026, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2035-05-28 | Direct | 11,700 |
Reported balance
After 2025-05-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-28 · Grant · Acquired 11,700 · Balance 11,700 F2: The option vests on the earlier of (a) May 28, 2026, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units vest on the earlier of (a) May 28, 2026, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.
F2: The option vests on the earlier of (a) May 28, 2026, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2025 Filed May 30, 2025 16:15 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 11,700 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001062993-25-010570 · form4.xml · derivative · entry 2 Burgess Vincent J · CIK 0001365408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,700 Underlying: Common Stock · 11,700 shares Expires 2035-05-28 F2 · derivative.exercise_date: The option vests on the earlier of (a) May 28, 2026, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 16:15 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 7,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-010570 · form4.xml · nonDerivative · entry 1 Burgess Vincent J · CIK 0001365408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,330 F1 · shares: These restricted stock units vest on the earlier of (a) May 28, 2026, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 17:00 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 6,200 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0001062993-24-012089 · form4.xml · derivative · entry 2 Burgess Vincent J · CIK 0001365408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,200 Underlying: Common Stock · 6,200 shares Expires 2034-06-04 F2 · derivative.exercise_date: The option vests on the earlier of (a) June 4, 2025, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 17:00 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-012089 · form4.xml · nonDerivative · entry 1 Burgess Vincent J · CIK 0001365408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,380 F1 · shares: These restricted stock units vest on the earlier of (a) June 4, 2025, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 16:36 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 5,360 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001062993-23-012774 · form4.xml · derivative · entry 2 Burgess Vincent J · CIK 0001365408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,360 Underlying: Common Stock · 5,360 shares Expires 2033-06-01 F2 · derivative.exercise_date: The option vests on the earlier of (a) June 1, 2024, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 16:36 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 3,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-012774 · form4.xml · nonDerivative · entry 1 Burgess Vincent J · CIK 0001365408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,130 F1 · shares: These restricted stock units vest on the earlier of (a) June 1, 2024, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 16:32 UTC | TELA Bio, Inc. TELA · Entity 7381 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,860 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001062993-23-008208 · form4.xml · derivative · entry 2 Burgess Vincent J · CIK 0001365408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,860 shares Expires 2023-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 16:32 UTC | TELA Bio, Inc. TELA · Entity 7381 | Exercise / conversionCommon Stock | 4,860 | $4.44 | $21,578.40 |
DisclosureSEC source: 0001062993-23-008208 · form4.xml · nonDerivative · entry 1 Burgess Vincent J · CIK 0001365408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 16:05 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 5,360 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0001062993-22-014127 · form4.xml · derivative · entry 2 Burgess Vincent J · CIK 0001365408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,360 Underlying: Common Stock · 5,360 shares Expires 2032-06-01 F2 · derivative.exercise_date: The option vests on the earlier of (a) June 1, 2023, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Peron's continued service through the applicable vesting date. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 16:05 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 3,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-014127 · form4.xml · nonDerivative · entry 1 Burgess Vincent J · CIK 0001365408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,135 F1 · shares: These restricted stock units vest on the earlier of (a) June 1, 2023, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Peron's continued service through the applicable vesting date. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 16:06 UTC | Acutus Medical, Inc. AFIB · Entity 83848 | Tax withholdingCommon Stock | 3,896 | $1.30 | $5,064.80 |
DisclosureSEC source: 0000950103-22-006023 · dp170688_4-burgess.xml · nonDerivative · entry 1 Burgess Vincent J · CIK 0001365408 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,469 F1 · shares: Represents shares that have been withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of (and related delivery of shares underlying) restricted stock units reported on a Form 4 filed on April 2, 2021. Read SEC document |
| August 05, 2021 Filed Aug 27, 2021 16:26 UTC | Acutus Medical, Inc. AFIB · Entity 83848 | Tax withholdingCommon Stock | 1,922 | $15.52 | $29,829.44 |
DisclosureSEC source: 0000950103-21-013063 · dp156937_4-burgess.xml · nonDerivative · entry 1 Burgess Vincent J · CIK 0001365408 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,365 Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 16:51 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 10,825 | $0.00 Strike: $13.16 | $0.00 |
DisclosureSEC source: 0001192482-21-000488 · edgar.xml · derivative · entry 1 Burgess Vincent J · CIK 0001365408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,825 Underlying: Common Stock · 10,825 shares Expires 2031-06-02 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 2, 2022, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 16:46 UTC | Acutus Medical, Inc. AFIB · Entity 83848 | GrantStock Options (Right to Buy) · Derivative | 158,691 | $0.00 Strike: $13.66 | $0.00 |
DisclosureSEC source: 0000950103-21-005125 · dp148971_4-burgess.xml · derivative · entry 2 Burgess Vincent J · CIK 0001365408 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,691 Underlying: Common Stock · 158,691 shares Expires 2031-04-01 F2 · derivative.exercise_date: This option vests over four years from April 1, 2021, with 1/4 vesting on the first anniversary of the vesting commencement date, and the remainder vesting in 36 equal monthly installments, subject to continued service through each such vesting date. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 16:46 UTC | Acutus Medical, Inc. AFIB · Entity 83848 | GrantCommon Stock | 45,065 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-005125 · dp148971_4-burgess.xml · nonDerivative · entry 1 Burgess Vincent J · CIK 0001365408 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,287 F1 · shares: Represents shares of Common Stock to be delivered in settlement of a restricted stock unit award upon continued service through the designated vesting event. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 19:55 UTC | Acutus Medical, Inc. AFIB · Entity 83848 | GrantStock Options (Right to Buy) · Derivative | 124,542 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0000950103-20-015481 · dp134114_4-burgess.xml · derivative · entry 2 Burgess Vincent J · CIK 0001365408 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,542 Underlying: Common Stock · 124,542 shares Expires 2030-08-05 F1 · derivative.exercise_date: This option vests over four years from August 5, 2020, with 1/4 vesting on the first anniversary of the vesting commencement date, and the remainder vesting in 36 equal monthly installments, subject to continued service through each such vesting date. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 19:55 UTC | Acutus Medical, Inc. AFIB · Entity 83848 | GrantCommon Stock | 22,222 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-015481 · dp134114_4-burgess.xml · nonDerivative · entry 1 Burgess Vincent J · CIK 0001365408 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,222 Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 16:37 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 8,806 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001192482-20-000448 · edgar.xml · derivative · entry 1 Burgess Vincent J · CIK 0001365408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,806 Underlying: Common Stock · 8,806 shares Expires 2030-06-04 F1 · derivative.exercise_date: The option vests on the earlier of (a) the first anniversary of June 4, 2020, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan), subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.